1990至2023年全球、区域及国家头痛疾病负担:2023年全球疾病负担研究的系统分析
该研究基于2023年全球疾病负担研究,采用分层贝叶斯元回归模型估计偏头痛、紧张型头痛和药物过度使用性头痛的全球患病率与伤残损失寿命年。
核心结论
- 头痛疾病尤其是偏头痛仍是全球重大健康挑战,需有效管理和预防策略。
- 避免药物过度使用(包括非处方药)可减少大量头痛相关负担,凸显公众教育的重要性。
研究设计与样本
- 基于2023年全球疾病负担研究的系统分析,从已发表的人群研究提取偏头痛、紧张型头痛和药物过度使用性头痛的患病率、发病率或缓解率数据。
主要发现
- 过去三十年头痛疾病患病率保持稳定。
临床怎么用
- 临床应重视偏头痛和紧张型头痛的长期管理,避免药物过度使用(包括非处方药)。
- 针对女性头痛负担更高的特点,需加强女性头痛患者的评估与干预。
局限性
- 数据来源于已发表的人群研究和个体参与者数据元分析,可能存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 estimates health loss from migraine, tension-type headache, and medication-overuse headache. This study presents updated results on headache-attributed burden from 1990 to 2023, along with clinical and public health implications. METHODS: Data on the prevalence, incidence, or remission of migraine, tension-type headache, and medication-overuse headache were extracted from published population-based studies. We used hierarchical Bayesian meta-regression modelling to estimate global, regional, and country-level prevalence of headache disorders. For the first time in GBD 2023, age-specific and sex-specific estimates of time in symptomatic state were applied by meta-analysing individual participant data from 41 653 individuals from the general populations of 18 countries from all parts of the world. Disability weights were applied to calculate years lived with disability (YLDs). Since medication-overuse headache is a sequela of a mistreated primary headache (due to medication overuse), its burden was reattributed to migraine or tension-type headache, informed by a meta-analysis of three longitudinal studies. FINDINGS: In 2023, 2·9 billion individuals (95% uncertainty interval 2·6-3·1) were affected by headache disorders, with a global age-standardised prevalence of 34·6% (31·6-37·5) and a YLD rate of 541·9 (373·4-739·9) per 100 000 population, with 487·5 (323·0-678·8) per 100 000 population attributed to migraine. The prevalence rates of these headache disorders have remained stable over the past three decades. YLD rates due to headache disorders were more than twice as high in females (739·9 [511·2-1011·5] per 100 000) as in males (346·1 [240·4-481·8] per 100 000). Medication-overuse headache contributed 58·9% of the YLD estimates for tension-type headache in males and 56·1% in females, as well as 22·6% of the YLD estimates for migraines in males and 14·1% in females. INTERPRETATION: Headache disorders, in particular migraine, continue to be a major global health challenge, emphasising the need for effective management and prevention strategies. Much headache-attributed burden could be averted or eliminated by avoiding overuse of medication (including over-the-counter medication), underscoring the importance of public education. FUNDING: Gates Foundation.
引用
- Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Neurol. 2025. PMID: 41240916. doi:10.1016/S1474-4422(25)00402-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。